Anti-Inflammatories: Small Molecule Approaches
Conference - San Diego, CA
JAK kinase inhibitors will probably be the first new class of oral anti-inflammatories on the market, with the first one likely to receive approval end of 2012. But which JAK or combinations of JAK enzymes is going to prove the best to inhibit in terms of side effects and overall risk benefit profile to patients? How are the other kinase inhibitors aimed at targeting SYK and BTK, targeted for autoimmune disease but with broader potential in diseases such as cancer, progressing?
Sponsoring Institution: Cambridge Healthtech Institute
www.drugdiscoverychemistry.com/ifl
April 17 - 18, 2012 (08:00 AM – 07:00 PM)
San Diego, CA
Contact: Nilufer Donmez (ndonmez@healthtech.com)
Phone: 781-247-6257
If you'd like to ask a question or post a comment about this talk please do so below.
This seminar posting is brought to you by Biotechnology Calendar, Inc. providing access to research information and research tools for nearly 20 years. Visit our Science Market Update Blog for current science funding and market information or see our schedule of upcoming science research laboratory product shows.
